Content about Valeant Pharmaceuticals International

January 31, 2014

Valeant Pharmaceuticals International announced that it received approval from the Food and Drug Administration for Retin-A Micro (tretinoin) gel microsphere 0.08%.

January 23, 2014

Valeant Pharmaceuticals International on Thursday announced the expiration of the tender offer by a subsidiary of Valeant Pharmaceuticals International to purchase all of the outstanding shares of Solta Medical for $2.92 per share in cash, without interest (less any applicable withholding taxes).

January 14, 2014

Three drug makers are looking into buying Pfizer's branded-generics drug business, according to published reports.

December 17, 2013

Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

December 16, 2013

Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

November 15, 2013

The Food and Drug Administration has approved a new drug for fungal infections of the skin made by Valeant Pharmaceuticals International, the drug maker said Friday.

October 29, 2013

Actavis hopes to become the first company to market a generic version of a drug used to treat acne in adolescents and adults, the company said.

October 2, 2013

Drug maker Valeant Pharmaceuticals International is joining an effort to oppose domestic violence, the company said Wednesday.

May 28, 2013

Canadian drug maker Valeant Pharmaceuticals International is buying U.S.-based Bausch & Lomb Holdings for $8.7 billion, the companies said Monday.

May 10, 2013

Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said.

May 1, 2013

Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.

April 29, 2013

A proposal by Canadian drug maker Valeant Pharmaceuticals International to purchase generic drug maker Actavis has fallen through, according to published reports.

April 5, 2013

Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.

April 4, 2013

The Food and Drug Administration approval this week of a generic genital herpes ointment made by Mylan could make a slight dent in the stock price of the company that makes the branded version.

November 16, 2012

The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.

September 25, 2012

Valeant Pharmaceuticals International has acquired rights to a drug used to treat a symptom of age-related macular degeneration, the drug maker said.

September 4, 2012

Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

June 15, 2012

Valeant Pharmaceuticals International has agreed to acquire a specialty oral health company that develops and commercializes products that improve and maintain oral health.

April 18, 2012

Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

April 12, 2012

Valeant announced that it has acquired a privately owned specialty pharmaceutical company based in the United States.

February 22, 2012

Kinerase, a division of Valeant Pharmaceuticals North America, has announced its second annual "Change Your Skin, Change Your Life" campaign, for which it will partner with four charities throughout the year to make financial contributions.

February 13, 2012

Valeant Pharmaceuticals is set to acquire a privately owned ophthalmic biotechnology company, the drug maker said Monday.

February 6, 2012

Mylan has completed its acquisition of two skin drugs from Valeant Pharmaceuticals, the generic drug maker said Monday.

January 30, 2012

Valeant Pharmaceuticals said it would not move forward in its pursuit of Ista Pharmaceuticals due to lack of progress.

© 2014 Drug Store News. All Rights Reserved.